Press Release: Cellphire : Cellphire Therapeutics Treats First Patient in Phase 2/3 Cryopreserved Platelets Clinical Trial
ROCKVILLE, Md., March 29, 2022 /PRNewswire/ -- Cellphire Therapeutics, Inc., a biotechnology company developing next-generation pooled allogeneic cellular therapeutics for application across multiple medical indications, announced today that the 1st patient has been treated in its Phase...
Read full article »
Cellphire is a Maryland-based biotechnology company that develops and commercializes stabilized cellular materials to treat bleeding and blood-related ailments.
Read more